Leukemia Therapeutics

Mr. Schultz has close to 25 years of experience in investor relations, financial communications and media relations. Most recently, from January 2011 to March 2013, Mr. Schultz served as Senior Director of Investor Relations and Corporate Communications at Amarin Corporation plc (Nasdaq: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.

Prior to Amarin, Mr. Schultz served as the Executive Director of the Jackson Hole Center for the Arts, a not-for-profit organization aimed at promoting artistic creativity and education. Mr. Schultz’s extensive investor relations and corporate communications experience also includes senior-level roles at Acusphere, Shareholder.com (a Nasdaq company), Manufacturer’s Services Limited, Wang Global and The ForeFront Group. Mr. Schultz holds a B.A. degree from St. Lawrence University.

Stephen Schultz has close to 25 years of experience in investor relations, financial communications and media relations. Mr. Schultz is currently the Vice President of Investor Relations for GW Pharmaceuticals (Nasdaq: GWPH), the global leader in developing cannabinoid-based pharmaceutical medicines.

Prior to GW, Mr. Schultz served as Senior Director of Investor Relations and Corporate Communications at Amarin Corporation (Nasdaq: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health.  Mr. Schultz has also served as the Executive Director of the Jackson Hole Center for the Arts, a not-for-profit organization aimed at promoting artistic creativity and education. Mr. Schultz’s extensive investor relations and corporate communications experience also includes senior-level roles at Acusphere, Shareholder.com (a Nasdaq company), Manufacturer’s Services Limited, Wang Global and The ForeFront Group. Mr. Schultz holds a B.A. degree from St. Lawrence University.